Galapagos NV is a biotech company headquartered in Belgium. The company focuses on the discovery and development of small molecule medicines with novel modes of action. Galapagos works on the development of treatments for a range of diseases, including inflammation, fibrosis, and osteoarthritis. The company's research and development efforts are centered on its proprietary platform technologies, including target discovery, drug discovery, and clinical development. Galapagos has multiple clinical-stage programs, including filgotinib, a drug being developed for the treatment of rheumatoid arthritis, Crohn's disease, and ulcerative colitis, among other indications. The company is also involved in collaborations with several pharmaceutical companies, including Gilead Sciences and Servier.
Galapagos NV is a biotech company headquartered in Belgium. The company focuses on the discovery and development of small molecule medicines with novel modes of action. Galapagos works on the development of treatments for a range of diseases, including inflammation, fibrosis, and osteoarthritis. The company's research and development efforts are centered on its proprietary platform technologies, including target discovery, drug discovery, and clinical development. Galapagos has multiple clinical-stage programs, including filgotinib, a drug being developed for the treatment of rheumatoid arthritis, Crohn's disease, and ulcerative colitis, among other indications. The company is also involved in collaborations with several pharmaceutical companies, including Gilead Sciences and Servier.